Phase Ib Clinical Study of Keynatinib

NCT04807881 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

DRUG: Keynatinib

Sponsor

Medolution Ltd.